Astellas confident over the mid-term despite generic challenges
This article was originally published in Scrip
Executive Summary
Astellas may be facing generic competition to two of its top drugs in the US, but it is confident that growth for other products and markets outside the US will help it overcome a dip in sales and profits this fiscal year.